Fosun Pharma withheld a net profit of 2.2 billion yuan in 2019

, Fosun Pharma announced its 2019 operating results. In 2019, when the pharmaceutical industry faces a critical period of full transformation, Fosun Pharma has handed over a report card that will satisfy the market.
reporting period, Fosun Pharma achieved operating income of 28.585 billion yuan, an increase of 14.72% over 2018. Net profit was RMB3,744 million, up 23.96% YoY, and net profit attributable to shareholders of listed companies was RMB3.322 billion, up 22.66% YoY. Net profit from deduction amounted to RMB2.233 billion.
results report showed that Fosun Pharma's cash flow from operating activities continued to rise, with net cash flow from operating activities of $3,222 million in 2019, an increase of 9.23% over 2018.

core product revenue is stableAt present, Fosun Pharma's business area covers the entire pharmaceutical and health industry chain, and in the metabolic and digestive system, anti-tumor, anti-infection, central nervous system, cardiovascular and blood system and other fields have a number of advantages of products. In 2019, its core business of pharmaceutical manufacturing and research and development continued to grow steadily, achieving operating income of 21.766 billion yuan, an increase of 16.51% over 2018.The steady growth of the core business was helped by continued high growth in revenue from core products such as non-busta tablets (Ultong), pivastatin calcium tablets (Bang), inoparin sodium injections, datomycin, and fumarate thioquine tablets (Kaiwei).In mid-May 2019, China's first self-developed biosynamic drug, lysoxi monoantigen injections (Hanlikang), went on sale and quickly gained market recognition, with annual sales of about 150 million yuan for Fosun Pharma. As a result, Fosun Pharma's annual sales of more than 100 million yuan of preparation products increased to 35, of which more than 500 million varieties reached 10.
Following the listing of Hanlikang, important progress has also been made in the listing of the injection of crater bead monoanti, Adamo single-dose injection, which has been accepted in China during the reporting period and has been included in the priority review process.Innovative research and development has always been a core driver of Fosun Pharma. During the reporting period, Fosun Pharma invested 3,463 million yuan in research and development, up 38.15 percent year-on-year. The pharmaceutical business invested 3,131 million yuan in research and development, an increase of 39.12%, accounting for 14.38% of the pharmaceutical business revenue ratio.While accelerating research and development, Revival Pharmaceuticals continues to promote the introduction and registration of drug licenses and the evaluation of generic drug consistency, and improves the "imitation combination" drug research and development system.
By the end of the report period, Fosun Pharma had 264 projects in the research of new drugs, generic drugs, biosimilars and generics consistency evaluation, of which 19 were small molecule innovative drugs, 12 were bioinnovatants, 21 were biosimilars, 133 were generic drugs by international standards, 49 were generic drugs and 2 were Chinese medicines;
By the end of 2019, Fosun Pharma had nine small molecule innovative pharmaceutical products (including 1 modified new drug), 9 adaptations approved for clinical trials in China, and 3 small molecule innovative drugs and 3 adaptives approved for overseas clinical trials, of which ORIN1001 has conducted clinical Phase I trials in the United States and been certified by the FDA Rapid Track Review.In medical devices and diagnostics, Fosun Pharma achieved operating income of nearly 3,736 million yuan, an increase of 2.66 percent over 2018 and an increase of 28.52 percent in the same calibre. Among them, the joint venture intuitive Fosun "Da Vinci surgical robot" as the world's only at the same time the FDA and the National Drug Administration approved the listing of minimally invasive cavity mirror surgical robot products, installed and surgical volume are growing rapidly: in 2019 installed 60 units, in Chinese mainland and Hong Kong surgery volume of more than 40,000 cases.In the medical services business, Fosun Pharma achieved operating income of 3.040 billion yuan in 2019, an increase of 18.61 percent over 2018. And formed a Pearl River Delta Bay Area, Yangtze River Delta, Huaihai Economic Zone as the focus of medical services, specialty and general hospitals combined strategic layout. By the end of 2019, more than 10 medical service organizations controlled by Fosun Pharmaceutical Group had approved a total of 4,328 beds.In addition, Fosun Pharma has pioneered new Internet-based medical services and products. As early as more than ten years ago, covering the entire medical and health industry chain of Fosun Pharma seized the "social medical" window opportunity, a series of heavy-handed attack, the first acquisition is Zen City Hospital. During the reporting period, ZenCheng Hospital has obtained the first Internet hospital license in Guangdong's private hospital system.Fosun International Co-CEO and Fosun Pharma Chairman Chen Qiyu pointed out that in the future, Fosun Pharma will continue to seize the opportunity of the state to encourage social capital to run a doctor, lean operation, to build a leading private medical management group in China.The internationalization road to enhance
the diversification of Fosun Pharma's business sector and investment is the embodiment of its "investor" vision. Domestic long-sleeve good dance, layout of the entire industrial chain, foreign, Fosun medicine naturally do not stop.In 2019, while continuous innovation, Fosun Pharma continued to promote its internationalization strategy, with overseas revenues of RMB6.622 billion, up 12.12% from 2018, and overseas revenues increasing to 23.17%.In 2016, Fosun Pharma acquired Gland Pharma, an overseas pharmaceutical company, the largest overseas acquisition by a Chinese pharmaceutical company at the time. In 2019, Gland Pharma also performed well, with net profit up 52.2% year-on-year, with a total of 15 generic products approved by the FDA during the reporting period. As of the 30th, A total of 2 products of Gland Pharma reported the application for import registration and 4 products reported the application for import registration of clinical trials.To further enrich its product line, Fosun Pharma last year teamed up with ReNeuron, a global leader in cell therapy, to introduce cell therapy products for post-stroke disability and retinal pigmentation to promote stem cell platforms, and was licensed by MimiVax to develop exclusive clinically and commercial glioblastoma immunotherapy product SurVaxM. In addition, Fosun Pharma has accelerated clinical trials and launches of licensed varieties of Avalanpa tablets and Tenapanor tablets.Surrounded by unseeded medical needs, Fosun Pharma is connecting global teams of scientists, leading technologies and high-value products through licensing, deep incubation, venture capital and other diversified, multi-level cooperation models to promote the development and transformation of innovative technologies and products around the world.In the international expansion, Fosun Pharma has also rapidly developed a marketing team overseas, in addition to establishing subsidiaries in mature markets such as the United States and Europe, but also in Africa, India and other emerging markets through self-construction and mergers and acquisitions to cultivate and form markets and production capacity. By the end of 2019, Fosun Pharma had formed a marketing team of nearly 5,300 people, including nearly 1,000 overseas pharmaceutical and medical device marketing teams.However, in the harvest of bright report card, Chen Qiyu is quite calm and rational about the future: "The outbreak of new crown pneumonia on the overall economic operation, the development of the entire health care industry opportunities and challenges coexist."He pointed out that In the future Fosun Pharma will firmly innovate and internationalize the development path, continue to strengthen industrial operations, invest more resources to support product innovation and market expansion, accelerate research and development of innovative drugs, will continue to focus on cancer, central nervous system, rare diseases and other therapeutic areas, and actively lay out PCG (protein drug therapy, cell therapy, gene therapy) direction. (Euro health) is